Linked Life Data

15256389

Source:http://linkedlifedata.com/resource/pubmed/id/15256389

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2004-10-11
pubmed:abstractText
For most patients, asthma is not controlled as defined by guidelines; whether this is achievable has not been prospectively studied. A 1-year, randomized, stratified, double-blind, parallel-group study of 3,421 patients with uncontrolled asthma compared fluticasone propionate and salmeterol/fluticasone in achieving two rigorous, composite, guideline-based measures of control: totally and well-controlled asthma. Treatment was stepped-up until total control was achieved (or maximum 500 microg corticosteroid twice a day). Significantly more patients in each stratum (previously corticosteroid-free, low- and moderate-dose corticosteroid users) achieved control with salmeterol/fluticasone than fluticasone. Total control was achieved across all strata: 520 (31%) versus 326 (19%) patients after dose escalation (p < 0.001) and 690 (41%) versus 468 (28%) at 1 year for salmeterol/fluticasone and fluticasone, respectively. Asthma became well controlled in 1,071 (63%) versus 846 (50%) after dose escalation (p < 0.001) and 1,204 (71%) versus 988 (59%) at 1 year. Control was achieved more rapidly and at a lower corticosteroid dose with salmeterol/fluticasone versus fluticasone. Across all strata, 68% and 76% of the patients receiving salmeterol/fluticasone and fluticasone, respectively, were on the highest dose at the end of treatment. Exacerbation rates (0.07-0.27 per patient per year) and improvement in health status were significantly better with salmeterol/fluticasone. This study confirms that the goal of guideline-derived asthma control was achieved in a majority of the patients.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1073-449X
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
170
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
836-44
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:15256389-Adrenal Cortex Hormones, pubmed-meshheading:15256389-Adult, pubmed-meshheading:15256389-Albuterol, pubmed-meshheading:15256389-Androstadienes, pubmed-meshheading:15256389-Anti-Asthmatic Agents, pubmed-meshheading:15256389-Asthma, pubmed-meshheading:15256389-Bronchodilator Agents, pubmed-meshheading:15256389-Dose-Response Relationship, Drug, pubmed-meshheading:15256389-Double-Blind Method, pubmed-meshheading:15256389-Drug Therapy, Combination, pubmed-meshheading:15256389-Female, pubmed-meshheading:15256389-Forced Expiratory Volume, pubmed-meshheading:15256389-Humans, pubmed-meshheading:15256389-Male, pubmed-meshheading:15256389-Practice Guidelines as Topic, pubmed-meshheading:15256389-Prospective Studies, pubmed-meshheading:15256389-Quality of Life, pubmed-meshheading:15256389-Questionnaires, pubmed-meshheading:15256389-Time Factors, pubmed-meshheading:15256389-Treatment Outcome
pubmed:year
2004
pubmed:articleTitle
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
pubmed:affiliation
UCT Lung Institute, P.O. Box 34560, Groote Schuur 7937, Cape Town, South Africa. ebateman@uctgsh1.uct.ac.za
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study